Quetiapine PCD Pharma Franchise Company
Cafoli Lifecare is a WHO-GMP certified PCD pharma franchise company offering a focused Quetiapine range of 6 formulations to distributors, stockists and franchise partners across India. Every product in the range is manufactured at approved facilities, packed for the Indian retail chain, and offered with district-level monopoly rights so that your investment in psychiatric doctor coverage stays protected.
What is Quetiapine?
Quetiapine is a second-generation (atypical) antipsychotic belonging to the dibenzothiazepine class. It acts on the central nervous system by antagonising dopamine D2 and serotonin 5-HT2A receptors, an action that helps stabilise the neurotransmitter signalling involved in psychosis and mood episodes. It is prescribed in schizophrenia, in the manic and depressive phases of bipolar disorder, and as an adjunct in major depressive disorder. Quetiapine is a prescription-only medicine that must be initiated, titrated and monitored by a registered psychiatrist. Full compound and pharmacology data are available on PubChem.
Quetiapine Formulations Available with Cafoli Lifecare
Our Quetiapine portfolio comprises 6 formulations, supplied in tablet form. Strength-wise details, packing configurations and net rates are shared with registered franchise enquiries, so partners can build a psychiatry list around the strengths their local prescribers actually use.
Therapeutic Applications of Quetiapine
- Schizophrenia and related psychotic disorders
- Manic and depressive episodes of bipolar disorder
- Maintenance therapy to reduce relapse in bipolar disorder
- Adjunctive therapy in major depressive disorder, where a specialist judges it appropriate
Prescribers are overwhelmingly psychiatrists and neuropsychiatrists, supported by de-addiction and rehabilitation centres and hospital psychiatry departments. Because Quetiapine is prescription-only, it must be stocked and dispensed strictly under a valid Drug License and against valid prescriptions.
Why Quetiapine is a High-Potential Molecule for Distributors
Mental health treatment in India is moving out of the shadows: awareness campaigns, insurance parity and the District Mental Health Programme have all widened the number of patients who reach a psychiatrist and stay on treatment. Quetiapine sits at the centre of that shift. It is a long-duration maintenance drug, so one stabilised patient generates predictable repeat demand month after month rather than a single course of therapy. The molecule is long off-patent, which keeps procurement economics workable while brand-level prescription loyalty stays high. And psychiatry is a compact call cycle — a distributor can cover the relevant specialists in a district with a small field team, which makes the segment unusually efficient compared with mass-market therapies.
Why Choose Cafoli Lifecare for Your Quetiapine Franchise
- Monopoly rights — one partner per district, with your territory contractually protected
- WHO-GMP certified manufacturing and DCGI-approved formulations
- Promotional inputs — visual aids, doctor sample packs, literature, reminder gifts and MR bags
- 1000+ franchise partners already working with us across India
- On-time despatch, transparent net rates and dedicated order support
References
- PubChem — Quetiapine compound record, National Library of Medicine
- WHO Model List of Essential Medicines
- PubMed — clinical literature on quetiapine
Our formulations of Quetiapine find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: